What is the primary purpose of the 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' section?

The MD&A section offers management's perspective on the company's financial performance and condition. It explains the key factors that influenced the results of operations, discusses trends, uncertainties, and significant events that have impacted or may impact the company's financial health. Investors should review this section for a deeper understanding of the reported financial numbers and management's outlook.

Where can I find specific revenue and profit figures for the quarter?

Specific revenue and profit figures for the quarter ending March 30, 2025, would be found within the 'Consolidated Statements of Earnings and Comprehensive Income/(Loss)' and detailed further in the 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' section. These sections are usually presented early in Part I of the 10-Q filing.

What kind of information is included in the 'Risk Factors' section?

The 'Risk Factors' section (Item 1A) outlines the significant risks and uncertainties that could adversely affect Bristol Myers Squibb's business, financial condition, or results of operations. This can include risks related to product development, regulatory approvals, competition, intellectual property, litigation, economic conditions, and geopolitical events.

Does this filing mention any significant legal proceedings?

Yes, Item 1 of Part II, 'Legal Proceedings,' is listed in the table of contents. Investors should refer to this section for disclosures regarding any material pending legal actions or significant litigation that could impact the company financially or operationally.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY2025

Summary

Bristol Myers Squibb (BMY) has filed its quarterly report for the period ending March 30, 2025. The filing provides investors with an overview of the company's financial performance, operational highlights, and risk factors. While the provided excerpt does not contain specific financial figures for the quarter, it outlines the key sections investors should review, including the Consolidated Statements of Earnings, Balance Sheets, and Cash Flows, as well as Management's Discussion and Analysis (MD&A) for detailed insights into the company's financial condition and results of operations. Investors should pay close attention to the MD&A section for management's commentary on revenue drivers, cost management, and strategic initiatives. The report also details market risk exposures and information regarding legal proceedings, risk factors, and unregistered sales of equity securities. Investors are encouraged to review these sections to gain a comprehensive understanding of potential risks and ongoing corporate activities that could impact the company's future performance. The inclusion of product brand names and trademark information in the notes to the financial statements suggests a focus on the company's pharmaceutical portfolio and intellectual property.

Financial Highlights

54 data points

Beta

Revenue

$11.20B

0.7% Gross Margin

Net Income

$2.46B

0.2% Net Margin

EPS (Diluted)

$1.20

Total Assets

$92.43B

Cash & Equivalents

$10.88B

Free Cash Flow

$1.69B

Financial Statements

Beta

Revenue	$11.20B
Cost of Revenue	$3.03B
Gross Profit	$8.17B
R&D Expenses	$2.26B
SG&A Expenses	$1.58B
Operating Expenses	$8.23B
Net Income	$2.46B
EPS (Basic)	$1.21
EPS (Diluted)	$1.20
Shares Outstanding (Basic)	2.03B
Shares Outstanding (Diluted)	2.04B

Key Highlights

1The filing covers the financial performance for the quarter ending March 30, 2025.
2Key financial statements, including Earnings, Balance Sheets, and Cash Flows, are presented.
3Management's Discussion and Analysis (MD&A) provides critical insights into financial condition and operational results.
4The report details the company's exposure to market risks.
5Information on legal proceedings and significant risk factors are disclosed.
6Details regarding unregistered sales of equity securities and their proceeds are included.
7The filing includes a summary of abbreviated terms and exhibits for reference.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2025

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions